Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | ABL1 | P00519 | 10/20 | 0.58 |
| ▸ | BCR | P11274 | 10/20 | 0.58 |
| ▸ | PRKCA | P17252 | 6/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.58 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.58 |
| ▸ | SRC | P12931 | 4/20 | 0.58 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.58 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.58 |
| ▸ | PRKCG | P05129 | 1/20 | 0.58 |
| ▸ | PRKCB | P05771 | 1/20 | 0.58 |
| ▸ | PRKCH | P24723 | 1/20 | 0.58 |
| ▸ | PRKCI | P41743 | 1/20 | 0.58 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.58 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.58 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.58 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.58 |
| ▸ | JAK2 | O60674 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4899553 | 0.92 | ABL1 (0.61) | MEN1KMT2AABL1BCRPRKCA | |
| SCHEMBL4901565 | 0.92 | MEN1 (0.59) | MEN1KMT2APRKCAJAK2CASP3 | |
| SCHEMBL6041113 | 0.89 | ABL1 (0.57) | MEN1KMT2AABL1BCRPRKCA | |
| SCHEMBL3123402 | 0.87 | ABL1 (0.74) | ABL1BCRPRKCAPDGFRBPDGFRA | |
| SCHEMBL4905315 | 0.87 | PDGFRA (0.61) | ABL1BCRPRKCAPDGFRBPDGFRA | |
| SCHEMBL4905073 | 0.86 | ABL1 (0.67) | ABL1BCRPRKCAPDGFRBPDGFRA | |
| SCHEMBL4906046 | 0.85 | ABL1 (0.76) | ABL1BCRPRKCAPDGFRBPDGFRA | |
| SCHEMBL4899247 | 0.85 | ABL1 (0.73) | ABL1BCRPRKCAPDGFRBPDGFRA | |
| SCHEMBL4903283 | 0.85 | ABL1 (0.61) | ABL1BCRPRKCAPDGFRBPDGFRA | |
| SCHEMBL4901723 | 0.82 | ABL1 (0.64) | ABL1BCRPRKCAPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1721609-A2 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC Biotech AG (DE) | 2006-11-15 | — | — | EP | claimed |
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2006-09-28 | — | — | US | claimed |
| EP-1395261-B1 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | GPC BIOTECH AG (DE) | 2006-06-28 | — | — | EP | claimed |
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2003-09-18 | — | — | US | claimed |
| US-20080187575-A1 | Pyrimidine Derivatives | VICHEM CHEMIE KFT (HU) | 2008-08-07 | — | — | US | disclosed |
| EP-1786781-A2 | PYRIMIDINE DERIVATIVES | GPC Biotech AG (DE) | 2007-05-23 | — | — | EP | disclosed |
| EP-1721609-A2 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC Biotech AG (DE) | 2006-11-15 | — | — | EP | disclosed |
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2006-09-28 | — | — | US | disclosed |
| EP-1395261-B1 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | GPC BIOTECH AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2006021458-A2 | PYRIMIDINE DERIVATIVES | GPC BIOTECH AG (DE) | 2006-03-02 | — | — | WO | disclosed |
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | PRNP, PPM1D, PPM1F | MEN1 4149/4885KMT2A 2560/4885ABL1 901/4885 |
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | PRNP, PPM1D, PPM1F | MEN1 4219/4885KMT2A 2319/4885ABL1 904/4885 |
| US-20080187575-A1 | Pyrimidine Derivatives | TYMP, TDP1, PNP | MEN1 3644/4885KMT2A 3738/4885ABL1 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.